Express Scripts Holding Company Company Profile (NASDAQ:ESRX)

Express Scripts Holding Company trades on the NASDAQ under the ticker symbol "ESRX."

Express Scripts Holding Company (NASDAQ:ESRX) issued its earnings results on Tuesday, July, 25th. The company reported $1.73 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.71 by $0.02. The company had revenue of $25.35 billion for the quarter, compared to analysts' expectations of $25.52 billion. Express Scripts Holding Company had a net margin of 3.50% and a return on equity of 25.58%. Express Scripts Holding Company's quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.57 EPS. View Express Scripts Holding Company's Earnings History.

Express Scripts Holding Company is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Express Scripts Holding Company.

Express Scripts Holding Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $6.95-7.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.97. Express Scripts Holding Company also updated its Q3 guidance to $1.88-1.92 EPS.

19 equities research analysts have issued 12 month price targets for Express Scripts Holding Company's stock. Their predictions range from $56.00 to $85.00. On average, they expect Express Scripts Holding Company's share price to reach $68.50 in the next twelve months. View Analyst Ratings for Express Scripts Holding Company.

Here are some recent quotes from research analysts about Express Scripts Holding Company stock:

• 1. Jefferies Group LLC analysts commented, "We believe ESRX remains a Buy given our view that company fundamentals, including its FCF, are stable and that the stock's valuation is attractive at 9x FY18 P/E. That said, we recognize that headlines surrounding drug pricing pressure and the overhang from ESRX's Anthem contract will drive continued stock volatility NT." (2/17/2017)
• 2. According to Zacks Investment Research, "Express Scripts’ fourth-quarter 2016 results were mixed, wherein adjusted earnings topped the Zacks Consensus Estimate, revenues beat the same. In the past three months, the company has underperformed the broader industry with respect to price performance. While the company’s guidance for 2017 was encouraging, tough competition in the Pharmacy Benefit Management space and the persistent drug pricing issue are expected to affect the share price. Express Scripts stands to benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. The company is focused on the development of both specialty drugs and generics, which are expected to account for 50% of the total drug expenditure by 2018. Further, its SafeGuardRx suite of products is designed to better manage specialty spend in turn, establishing a higher standard for patient outcomes." (2/16/2017)
• 3. Credit Suisse Group analysts commented, "We continue to believe ESRX will seek to buy Rite Aid’s PBM unit from Walgreens if the deal closes successfully and possibly add its generic purchasing clout to Walgreen’s buying consortium for added economics. Derivatives: At a time when hapless politicians are wringing their wrists about out of control drug costs, we cite another example of a large government payor tapping PBM solutions for greater savings. As opposed to Anthem, TRICARE utilizes a number of ESRX’s cost management tools in addition to a preferred pharmacy network to better manage its trend. We see the PBM model as more rather than less relevant to the current situation, and we see longer-term enhanced roles for PBMs in Medicare part D and B. Separately, we see AmerisourceBergen as benefiting from the news as Walgreen’s supplier, while Cardinal Health stand to lose some share as CVS’s partner." (10/3/2016)

Express Scripts Holding Company saw a increase in short interest in August. As of August 31st, there was short interest totalling 33,401,117 shares, an increase of 3.9% from the August 15th total of 32,160,472 shares. Based on an average trading volume of 2,457,981 shares, the days-to-cover ratio is currently 13.6 days. Approximately 5.6% of the company's shares are sold short.

Some companies that are related to Express Scripts Holding Company include Allergan PLC. (AGN), Biogen (BIIB), Aetna (AET), Anthem (ANTM), Shire PLC (SHPG), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Boston Scientific Corporation (BSX), Intuitive Surgical (ISRG), Vertex Pharmaceuticals Incorporated (VRTX), Baxter International (BAX), Humana (HUM), McKesson Corporation (MCK), Alexion Pharmaceuticals (ALXN), Zoetis (ZTS), Fresenius Medical Care Corporation (FMS), Illumina (ILMN) and Actelion (ALIOF).

Express Scripts Holding Company's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.93%), BlackRock Inc. (6.56%), Dodge & Cox (6.27%), Capital World Investors (5.82%), State Street Corp (4.58%) and Capital Research Global Investors (2.40%). Company insiders that own Express Scripts Holding Company stock include Christopher A Mcginnis, Everett Neville, Mahon Thomas P Mac, Phyllis S Anderson and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts Holding Company.

Express Scripts Holding Company's stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Bank of New York Mellon Corp, The Manufacturers Life Insurance Company , TIAA CREF Investment Management LLC, Capital Guardian Trust Co., Schroder Investment Management Group, Ameriprise Financial Inc. and Capital Counsel LLC NY. Company insiders that have sold Express Scripts Holding Company stock in the last year include Everett Neville, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts Holding Company.

Express Scripts Holding Company's stock was purchased by a variety of institutional investors in the last quarter, including Dodge & Cox, Pzena Investment Management LLC, Northern Trust Corp, Veritas Asset Management LLP, Macquarie Group Ltd., Arrowstreet Capital Limited Partnership, Koch Industries Inc. and PGGM Investments. View Insider Buying and Selling for Express Scripts Holding Company.

Shares of Express Scripts Holding Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Express Scripts Holding Company stock can currently be purchased for approximately $62.29.